RxDoctor Payments Data

Shruti Badhwar, DO

Clinical Neurophysiology · Phoenix, AZNPI 1497918502

Payments from drug & device makers

$22,361in general payments, 2019–2025

Across 472 payments — averaging $47.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$11K
  • SK Life Science, Inc.$3K
  • UCB, Inc.$1K
  • AbbVie$956
  • Livanova USA, Inc.$639
  • Novartis$509
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$13,06058%
  • Travel & lodging$1,6527%
  • Food & beverage$7,64934%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$63,339
Medicare patients
167
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe68$49,383
NamzaricMemantine Hcl/Donepezil Hcl54$28,323
UbrelvyUbrogepant24$26,674
Nurtec OdtRimegepant Sulfate20$24,423
Ajovy AutoinjectorFremanezumab-Vfrm19$19,850
Gabapentin214$2,782
Levetiracetam105$2,776
Donepezil Hcl185$2,197
Levetiracetam ErLevetiracetam18$1,688
Carbidopa-LevodopaCarbidopa/Levodopa61$1,033
Pramipexole DihydrochloridePramipexole Di-Hcl22$836
Divalproex Sodium ErDivalproex Sodium11$827
Nortriptyline Hcl71$786
Primidone16$610
Zonisamide22$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Ubrelvy$956$54,99878 claims
PfizerNurtec Odt$168$24,42320 claims
Upsher-smith Laboratories LLCTopiramate$104$30935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Phoenix

Where these figures come from

Is this you, or does something look wrong? →